MTOR and breast cancer: On the basis of the preclinical observation that PTEN loss may increase tumor sensitivity to mTOR inhibition [14,54], the predictive potential of PTEN in BC patients has been explored in the context of several clinical trials testing the mTOR inhibitor Everolimus for metastatic BC, with conflicting results.